montelukast paediatric 5 milligram tablets chewable
cipla (eu) limited - montelukast sodium, montelukast - tablets chewable - 5 milligram - leukotriene receptor antagonists
zoledronic acid 5mg/100 millilitre solution for infusion
cipla (eu) limited - zoledronic acid monohydrate - solution for infusion - 5mg/100 millilitre - biphosphonates
bivalirudin cipla 250 milligram pdr/conc/soln/inj/inf
cipla (eu) limited - bivalirudin - pdr/conc/soln/inj/inf - 250 milligram - direct thrombin inhibitors
imatinib 100mg capsules, hard
cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - imatinib mesilate - hard capsule - imatinib mesilate 100 mg - antineoplastic agents
imatinib 400mg capsules, hard
cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - imatinib mesilate - hard capsule - imatinib mesilate 400 mg - antineoplastic agents
paclitaxel 6mg/ml concentrate for solution for infusion
cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - antineoplastic agents
paclitaxel 6mg/ml concentrate for solution for infusion
cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg - antineoplastic agents
paclitaxel 6mg/ml concentrate for solution for infusion
cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - antineoplastic agents
cetirizine dihydrochloride 1mg/ml oral solution
cipla (eu) limited - cetirizine dihydrochloride - oral solution - 1mg/ml - piperazine derivatives - it is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis and for the relief of symptoms of chronic idiopathic urticaria.
imatinib 100 milligram capsules hard
cipla (eu) limited - imatinib mesilate - capsules hard - 100 milligram - other cytostatics - antineoplastic agents; protein kinase inhibitor - it s indicated for the treatment of: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid; leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated; phase or blast crisis.; adult patients with ph+ cml in blast crisis.; adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy; adult patients with relapsed or refractory ph+ all as monotherapy; adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived; growth factor receptor (pdgfr) gene re-arrangements.; adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement